TY - JOUR
T1 - A Phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies
AU - Wagner, John A.
AU - Nepomuceno, Ilynn B.
AU - Messner, Anna H.
AU - Moran, Mary Lynn
AU - Batson, Eric P.
AU - Dimiceli, Sue
AU - Brown, Byron W.
AU - Desch, Julie K.
AU - Norbash, Alexander M.
AU - Conrad, Carol K.
AU - Guggino, William B.
AU - Flotte, Terence R.
AU - Wine, Jeffrey J.
AU - Carter, Barrie J.
AU - Reynolds, Thomas C.
AU - Moss, Richard B.
AU - Gardner, Phyllis
PY - 2002/7/20
Y1 - 2002/7/20
N2 - tgAAVCF, an adeno-associated cystic fibrosis transmembrane conductance regulator (CFTR) viral vector/gene construct, was administered to 23 patients in a Phase II, double-blind, randomized, placebo-controlled clinical trial. For each patient, a dose of 100, 000 replication units of tgAAVCF was administered to one maxillary sinus, while the contralateral maxillary sinus received a placebo treatment, thereby establishing an inpatient control. Neither the primary efficacy endpoint, defined as the rate of relapse of clinically defined, endoscopically diagnosed recurrent sinusitis, nor several secondary endpoints (sinus transepithelial potential difference [TEPD], histopathology, sinus fluid interleukin [IL]-8 measurements) achieved statistical significance when comparing treated to control sinuses within patients. One secondary endpoint, measurements of the anti-inflammatory cytokine IL-10 in sinus fluid, was significantly (p < 0.03) increased in the tgAAVCF-treated sinus relative to the placebo-treated sinus at day 90 after vector instillation. The tgAAVCF administration was well tolerated, without adverse respiratory events, and there was no evidence of enhanced inflammation in sinus histopathology or alterations in serum-neutralizing antibody titer to adeno-associated virus (AAV) capsid protein after vector administration. In summary, this Phase II trial confirms the safety of tgAAVCF but provides little support of its efficacy in the within-patient controlled sinus study. Various potentially confounding factors are discussed.
AB - tgAAVCF, an adeno-associated cystic fibrosis transmembrane conductance regulator (CFTR) viral vector/gene construct, was administered to 23 patients in a Phase II, double-blind, randomized, placebo-controlled clinical trial. For each patient, a dose of 100, 000 replication units of tgAAVCF was administered to one maxillary sinus, while the contralateral maxillary sinus received a placebo treatment, thereby establishing an inpatient control. Neither the primary efficacy endpoint, defined as the rate of relapse of clinically defined, endoscopically diagnosed recurrent sinusitis, nor several secondary endpoints (sinus transepithelial potential difference [TEPD], histopathology, sinus fluid interleukin [IL]-8 measurements) achieved statistical significance when comparing treated to control sinuses within patients. One secondary endpoint, measurements of the anti-inflammatory cytokine IL-10 in sinus fluid, was significantly (p < 0.03) increased in the tgAAVCF-treated sinus relative to the placebo-treated sinus at day 90 after vector instillation. The tgAAVCF administration was well tolerated, without adverse respiratory events, and there was no evidence of enhanced inflammation in sinus histopathology or alterations in serum-neutralizing antibody titer to adeno-associated virus (AAV) capsid protein after vector administration. In summary, this Phase II trial confirms the safety of tgAAVCF but provides little support of its efficacy in the within-patient controlled sinus study. Various potentially confounding factors are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0036377851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036377851&partnerID=8YFLogxK
U2 - 10.1089/104303402760128577
DO - 10.1089/104303402760128577
M3 - Article
C2 - 12162817
AN - SCOPUS:0036377851
SN - 1043-0342
VL - 13
SP - 1349
EP - 1359
JO - Human gene therapy
JF - Human gene therapy
IS - 11
ER -